| Name | Title | Contact Details |
|---|---|---|
Mark Jacobson |
Chief Operating Officer | Profile |
Revance Therapeutics is a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, including muscle movement disorders and pain. The company`s lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis with the potential to be the first long-acting neuromodulator. Revance has developed a proprietary, stabilizing excipient peptide technology designed to create novel, differentiated therapies. The company has a comprehensive pipeline based upon its peptide technology, including injectable and topical formulations of daxibotulinumtoxinA.
We are a biotechnology company with a diverse portfolio of best-in-class highly differentiated clinical and pre-clinical stage programs focused on high value targets.
Same taste, but plant-based. A food revolution has started. Know the future of food. Why not?
Dance Biopharm is a private company focused on developing novel inhaled formulations of medicines to treat diabetes and other serious chronic diseases.
Genyous Life Sciences is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.